Evaluation of recombinant activated protein C for severe sepsis at a tertiary academic medical center

References

• DellingerRPLevyMMCarletJMSurviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008Crit Care Med200836129632718158437
   PubMed Web of Science ®Google Scholar
• LevyMMDellingerRPTownsendSRThe Surviving Sepsis Campaign: Results of an international guideline-based performance improvement program targeting severe sepsisCrit Care Med201038236737320035219
   PubMed Web of Science ®Google Scholar
• FerrerRArtigasASuarezDEffectiveness of treatments for severe sepsis: a prospective, multicenter, observational studyAm J Respir Crit Care Med2009180986186619696442
   PubMed Web of Science ®Google Scholar
• SchorrCPerformance improvement in the management of sepsisCrit Care Clin200925485786719892257
   PubMed Web of Science ®Google Scholar
• YanSBHelterbrandJDHartmanDLLow levels of protein C are associated with poor outcome in severe sepsisChest2001120391592211555529
   PubMed Web of Science ®Google Scholar
• ShorrAFBernardGRDhainautJFProtein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcomeCrit Care2006103R9216780598
   PubMed Web of Science ®Google Scholar
• MaciasWLNelsonDRSevere protein C deficiency predicts early death in severe sepsisCrit Care Med200432Suppl 5S223S22815118522
   PubMed Web of Science ®Google Scholar
• LeviMvan der PollTRecombinant human activated protein C: current insights into its mechanism of actionCrit Care200711 Suppl 5S318269690
   PubMed Web of Science ®Google Scholar
• MaciasWLYanSBWilliamsMDNew insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated)Crit Care20059 Suppl 4S38S4516168074
   PubMed Web of Science ®Google Scholar
• BernardGRVincentJLLaterrePFEfficacy and safety of recombinant human activated protein C for severe sepsisN Engl J Med200134469970911236773
   PubMed Web of Science ®Google Scholar
• AbrahamELaterrePFGargRDrotrecogin alfa (activated) for adults with severe sepsis and a low risk of deathN Engl J Med20053531332134116192478
   PubMed Web of Science ®Google Scholar
• VincentJLBernardGRBealeRDrotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatmentCrit Care Med2005332266227716215381
   PubMed Web of Science ®Google Scholar
• BernardGRMargolisBDShaniesHMExtended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsisChest200412562206221615189943
   PubMed Web of Science ®Google Scholar
• BertoliniGRossiCAnghileriAUse of drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide surveyIntensive Care Med200733342643417325836
   PubMed Web of Science ®Google Scholar
• KanjiSPerreaultMMChantCEvaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational studyIntensive Care Med200733351752317325837
   PubMed Web of Science ®Google Scholar
• RowanKMWelchCANorthEDrotrecogin alfa (activated): real-life use and outcomes for the UKCrit Care2008122R5818430215
   PubMed Web of Science ®Google Scholar
• GentryCAGrossKBSudBAdverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautionsCrit Care Med2009371192519050637
   PubMed Web of Science ®Google Scholar
• NadelSGoldsteinBWilliamsMDDrotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III randomized controlled trialLancet200736983684317350452
   PubMed Web of Science ®Google Scholar
• SweeneyDANatansonCEichackerPQRecombinant human activated protein C, package labeling, and hemorrhage risksCrit Care Med200937132732919112285
   PubMed Web of Science ®Google Scholar
• PooleDBertoliniGGarattiniSErrors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsisLancet Infect Dis200991677219095197
   PubMed Web of Science ®Google Scholar
• OpalSMCan we RESOLVE the treatment of sepsis?Lancet2007369956480380417350431
   PubMed Web of Science ®Google Scholar
• FinferSRanieriVMThompsonBTDesign, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shockIntensive Care Med200834111935194718839141
   PubMed Web of Science ®Google Scholar
• LillyLilly announces withdrawal of Xigris^®following recent clinical trial results Available from: https://investor.lilly.com/releasedetail2.cfm?ReleaseID=617602Accessed October 25, 2011
   Google Scholar
• FischerMALillyCMChurchillWWAn algorithmic computerised order entry approach to assist in the prescribing of new therapeutic agents: case study of activated protein C at an academic medical centreDrug Saf200427151253126115588120
   PubMed Web of Science ®Google Scholar
• Eli Lilly and CoDrotrecogin alfa (activated), Xigris: product labelIndianapolis, INEli Lilly and Co2001
   Google Scholar
• EichackerPQNatansonCDannerRLSurviving sepsis – practice guidelines, marketing campaigns, and Eli LillyN Engl J Med2006355161640164217050887
   PubMed Web of Science ®Google Scholar
• LeviMLevyMWilliamsMDProphylactic heparin in patients with severe sepsis treated with Drotrecogin alfa (activated)Am J Respir Crit Care Med200717648349017556722
   PubMed Web of Science ®Google Scholar
• Product Information – XigrisEli Lilly and CoIndianapolis, IN2007 Available at: http://www.xigris.com/330-safety.jspAccessed January 4, 2010
   Google Scholar
• GreenwoodBSzumitaPMLevyHError rates among clinical pharmacists in calculating the APACHE II scorePharmacotherapy20072728528917253918
   PubMed Web of Science ®Google Scholar
• OwenPSTanECKiserTHReliability and accuracy of practitioner-calculated Acute Physiology and Chronic Health Evaluation II scores for determining the appropriateness of drotrecogin alfa (activated)Am J Health Syst Pharm201067213614320065268
   PubMed Web of Science ®Google Scholar